公开(公告)号：WO1994006430A1

公开(公告)日：1994-03-31

申请号：PCT/US1993008999

申请日：1993-09-22

Applicant: SEPRACOR, INC.

Inventor： SEPRACOR, INC. ,  GRAY, Nancy, M.

IPC: A61K31/495

CPC classification number: A61K31/495

Abstract: Methods and compositions are disclosed utilizing optically pure (+) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (+) isomer is also useful for the treatment of allergic asthma and chronic and physical urticaria. (+) Cetirizine is an inhibitor of eosinophil chemotaxis and is therefore useful in the treatment of other conditions related to eosinophilia such as allergic asthma, seasonal allergic rhinitis, atopic dermatitis, some parasitic diseases, some chronic obstructive lung diseases and certain gastrointestinal and genitourinary disorders.

Abstract translation: 公开了使用光学纯（+）西替利嗪治疗人类季节性和常年性过敏性鼻炎的方法和组合物，同时避免与西替利嗪的外消旋混合物相关的副作用的伴随的责任。 光学纯（+）异构体也可用于治疗过敏性哮喘和慢性和身体性荨麻疹。 （+）西替利嗪是嗜酸性粒细胞趋化性的抑制剂，因此可用于治疗与嗜酸性粒细胞增多有关的其他病症，如过敏性哮喘，季节性过敏性鼻炎，特应性皮炎，一些寄生虫病，一些慢性阻塞性肺疾病和某些胃肠道和泌尿生殖系统疾病 。

公开(公告)号：WO1993017150A1

公开(公告)日：1993-09-02

申请号：PCT/US1993001483

申请日：1993-02-19

Applicant: SEPRACOR, INC.

Inventor： SEPRACOR, INC. ,  GAO, Yun ,  ZEPP, Charles, M.

IPC: C25B03/02

CPC classification number: B01J31/183 ,  B01J31/16 ,  B01J31/4038 ,  B01J31/4061 ,  B01J31/4076 ,  B01J37/348 ,  B01J2531/825 ,  C07B2200/07 ,  C07C29/48 ,  C07C2602/10 ,  Y02P20/584 ,  C07C31/42 ,  C07C33/26 ,  C07C33/16

Abstract: A process is disclosed in wich optically active glycols are produced through an electrolytic asymmetric dihydroxylation (ADH) reaction involving olefins as substrates. The ADH reaction is mediated by a catalytically active amount of osmium tetroxide or osmium-containing precursor in a protic medium in the presence of chiral ligand. Any lower valent osmium species produced in the course of the ADH reaction is regnerated electrolytically either directly in the absence of a secondary oxidant or indirectly in the presence of a secondary oxidant that itself undergoes electrolytic regeneration.

公开(公告)号：WO1993000091A1

公开(公告)日：1993-01-07

申请号：PCT/US1992005379

申请日：1992-06-25

Applicant: SEPRACOR, INC.

Inventor： SEPRACOR, INC. ,  YOUNG, James, W.

IPC: A61K31/44

CPC classification number: A61K31/44

Abstract: A method and composition are disclosed utilizing the pure (-) isomer of pirbuterol, which is a potent bronchodilator and a potent cardiovascular stimulant with reduced adverse effects, having a low incidence of the development of tolerance and having increased bronchial distribution when administered by inhalation.

Abstract translation: 披露了一种方法和组合物，其利用吡布特罗的纯（ - ）异构体，其是有效的支气管扩张剂和具有降低的副作用的有效的心血管兴奋剂，在通过吸入给药时具有低耐受性发生率并且具有增加的支气管分布。

公开(公告)号：WO1993000081A1

公开(公告)日：1993-01-07

申请号：PCT/US1992005429

申请日：1992-06-25

Applicant: SEPRACOR, INC. ,  YOUNG, James, W. ,  BARBERICH, Timothy, J.

Inventor： SEPRACOR, INC.

IPC: A61K31/135

CPC classification number: A61K31/50 ,  A61K31/135 ,  A61K31/195 ,  A61K31/505 ,  A61K31/54 ,  A61K2300/00

Abstract: Optically pure S(-) nadolol, which is substantially free of the R(+) enantiomer, is a potent beta-blocker for relieving the symptoms of angina pectoris and hypertension in individuals. A method is disclosed utilizing the optically pure S(-) enantiomer of nadolol for treating cardiovascular disorders while reducing undesirable side effects associated with the administration of the racemic drug.

Abstract translation: 基本上不含R（+）对映异构体的光学纯S（ - ）纳多洛尔是缓解个体心绞痛和高血压症状的有效β受体阻滞剂。 公开了利用纳多洛尔的光学纯S（ - ）对映异构体治疗心血管疾病同时减少与外消旋药物施用相关的不良副作用的方法。

公开(公告)号：WO1992021327A1

公开(公告)日：1992-12-10

申请号：PCT/US1992004265

申请日：1992-05-20

Applicant: SEPRACOR, INC. ,  BOSCHETTI, Egisto ,  BROUARD, Michel ,  DROUET, Ludovic ,  GIROT, Pierre ,  LAURENT, Alexandre ,  WASSER, Michel

Inventor： SEPRACOR, INC.

IPC: A61K09/16

CPC classification number: A61L24/06 ,  A61K9/1676 ,  A61L2400/06 ,  A61L2430/36 ,  C08L33/26 ,  C08L33/14

Abstract: The present invention concerns the use of microspheres for therapeutic embolization consisting of a hydrophilic acrylic copolymer coated with a cell adhesion promoter.

公开(公告)号：WO1988004286A1

公开(公告)日：1988-06-16

申请号：PCT/US1987003051

申请日：1987-11-20

Applicant: SEPRACOR, INC.

Inventor： SEPRACOR, INC. ,  MATSON, Stephen, L. ,  STANLEY, Thomas, J.

IPC: C07C17/20

CPC classification number: B01J31/0268 ,  B01J4/04 ,  B01J14/005 ,  B01J19/2475 ,  B01J31/0204 ,  B01J31/0229 ,  B01J31/0239 ,  B01J31/40 ,  B01J31/4061 ,  B01J35/065 ,  B01J2231/40 ,  B01J2231/4205 ,  B01J2231/70 ,  B01J2531/985 ,  C07C17/208 ,  Y02P20/584 ,  C07C19/07

Abstract: Novel method for conducting phase transfer catalysis in a multiphase reaction system wherein the different phases are separated by a membrane permeable to the phase transfer catalyst and its various reaction complexes. The invention also relates to membranes and a membrane-containing apparatus useful in carrying out phase transfer catalysis.

Abstract translation: 用于在多相反应体系中进行相转移催化的新方法，其中通过相转移催化剂及其各种反应络合物可渗透的膜分离不同相。 本发明还涉及可用于进行相转移催化的膜和含膜装置。

公开(公告)号：WO1987002381A1

公开(公告)日：1987-04-23

申请号：PCT/US1986002089

申请日：1986-10-08

Applicant: SEPRACOR, INC.

Inventor： SEPRACOR, INC. ,  MATSON, Stephen, L.

IPC: C12M01/40

CPC classification number: B01D69/141 ,  C12M25/10 ,  C12M29/16

Abstract: Apparatus for catalysis in multiphase reaction systems in which catalysts are confined within various membranes without the use of covalent coupling. Confinement of the catalysts is achieved by a combination of a small-pore skin on one side of the membrane and the use of a solvent in which the catalysts are not appreciably soluble on the other. Methods are also provided for the preparation of such apparatus and for their regeneration by incorporation of fresh catalyst.

Abstract translation: 在多相反应体系中催化的装置，其中催化剂被限制在各种膜中而不使用共价偶联。 催化剂的限制通过膜的一侧上的小孔表皮与使用其中催化剂在另一方面不易溶解的溶剂的组合来实现。 还提供了用于制备这种装置并通过掺入新鲜催化剂进行再生的方法。

公开(公告)号：WO1998021203A1

公开(公告)日：1998-05-22

申请号：PCT/US1997020460

申请日：1997-11-12

Applicant: SEPRACOR, INC.

Inventor： SEPRACOR, INC. ,  HONG, Yaping ,  KOCH, Patrick ,  MCCULLOUGH, John, R. ,  SENANAYAKE, Chris, H. ,  TANOURY, Gerald, J.

IPC: C07D405/14

CPC classification number: C07D249/08 ,  C07D231/12 ,  C07D233/56 ,  C07D249/12

Abstract: A method of preparation of optically pure isomers of hydroxyitraconazole, in particular the two cis dioxolane diastereomers of the sec-butyl (S,R)-isomer, and to phosphate and sulfate derivatives thereof is disclosed. Pharmaceutical compositions containing these compounds and to their use for the treatment of fungal infection are also disclosed.

Abstract translation: 公开了制备羟基特他康唑的旋光纯异构体的方法，特别是仲丁基（S，R） - 异构体的两种顺式二氧戊环非对映体及其磷酸盐和硫酸盐衍生物。 还公开了含有这些化合物的药物组合物及其用于治疗真菌感染的用途。

公开(公告)号：WO1998000140A1

公开(公告)日：1998-01-08

申请号：PCT/US1997011640

申请日：1997-06-27

Applicant: SEPRACOR, INC. ,  FABIANO, Vincent, L. ,  McCULLOUGH, John, R.

Inventor： SEPRACOR, INC.

IPC: A61K31/445

CPC classification number: A61K31/445 ,  A61K31/4453

Abstract: A method for treating urinary incontinence, such as incontinence resulting from bladder detrusor muscle instability, using enantiomerically enriched (R)-trihexyphenidyl. The method comprises administering a therapeutically effective amount of enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, substantially free of the (S)-trihexyphenidyl enantiomer. Pharmaceutical compositions for the treatment of urinary incontinence comprising enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and an acceptable carrier are also disclosed.

Abstract translation: 使用对映异构体富集的（R） - 己烯茴香酰基治疗尿失禁的方法，例如由膀胱逼尿肌不稳定引起的失禁。 该方法包括施用治疗有效量的基本上不含（S） - 间苯代苯基对映异构体的对映异构体富集的（R） - 己烯苯基或其药学上可接受的盐。 还公开了用于治疗尿失禁的药物组合物，其包含对映异构体富集的（R） - 己烯茴香基或其药学上可接受的盐和可接受的载体。

公开(公告)号：WO1998000139A1

公开(公告)日：1998-01-08

申请号：PCT/US1997011259

申请日：1997-06-27

Applicant: SEPRACOR, INC. ,  FABIANO, Vincent, L. ,  McCULLOUGH, John, R.

Inventor： SEPRACOR, INC.

IPC: A61K31/435

CPC classification number: A61K31/439 ,  C07D453/02

Abstract: A method for treating urinary incontinence, such as incontinence resulting from bladder detrusor muscle instability, using enantiomerically enriched (S)-clidinium. The method comprises administering a therapeutically effective amount of enantiomerically enriched (S)-clidinium, or a pharmaceutically acceptable salt thereof, substantially free of the (R)-clidinium enantiomer. Pharmaceutical compositions for the treatment of urinary incontinence comprising enantiomerically enriched (S)-clidinium, or a pharmaceutically acceptable salt thereof, and an acceptable carrier are also disclosed.

Abstract translation: 使用对映异构体富集（S） - idin啶治疗尿失禁的方法，例如由膀胱逼尿肌不稳定引起的失禁。 该方法包括施用治疗有效量的基本上不含（R） - 吡啶鎓对映异构体的对映异构体富集的（S）吖啶鎓或其药学上可接受的盐。 还公开了用于治疗尿失禁的药物组合物，其包含对映异构体富集的（S） - 脒鎓盐或其药学上可接受的盐和可接受的载体。